JPMorgan analyst Jeffrey Zekauskas downgraded Westlake (WLK) to Underweight from Neutral with an unchanged price target of $90. The firm cites valuation for the downgrade. In an environment of sharply higher earnings for petrochemicals, Dow and Lyondell’s balance sheets have meaningfully improved relative to Westlake, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WLK:
- Westlake: Neutral Rating Reaffirmed as Q1 Miss Tempers Near-Term Outlook; $125 Price Target Maintained
- Westlake Chemical Balances Q1 Setbacks With Recovery Momentum
- Westlake price target raised to $115 from $80 at Morgan Stanley
- Westlake Posts Q1 2026 Loss Amid Restructuring Efforts
- Westlake reports Q1 EPS (77c), consensus (24c)